Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Liabilities and Shareholders Equity (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $21.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 43.04% year-over-year to $21.8 million, compared with a TTM value of $110.9 million through Sep 2025, down 39.63%, and an annual FY2024 reading of $35.0 million, down 36.0% over the prior year.
  • Liabilities and Shareholders Equity was $21.8 million for Q3 2025 at Lisata Therapeutics, down from $25.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $66.3 million in Q1 2023 and bottomed at $21.8 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $43.8 million, with a median of $42.6 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity fell 27.27% in 2024, then plummeted 43.04% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $54.7 million in 2023, then plummeted by 36.0% to $35.0 million in 2024, then plummeted by 37.83% to $21.8 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for LSTA at $21.8 million in Q3 2025, $25.2 million in Q2 2025, and $29.0 million in Q1 2025.